ArticleScientific reports2025
Multi-pathway regulatory role of miR-4693-5p in the modulation of rheumatoid arthritis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune condition that typically causes inflammation in joints symmetrically. Dysregulated microRNAs are implicated in RA development. Our earlier findings showed that miR-4693-5p levels were decreased in PBMCs isolated from RA patients, impacting apoptosis, inflammatory cytokines production, and reactive oxygen species (ROS) response. This study investigated the regulatory influence of TNF-α on the expression of miR-4693-5p and examined the downstream effects of miR-4693-5p on key proteins and pathways associated with RA. The objective is to elucidate the therapeutic potential of miR-4693-5p in disease. The impact of TNF-α on miR-4693-5p expression in SW982 cells was assessed using qRT-PCR. Differential protein analysis was performed using SWATH-MS in RA-FLS regulated by miR-4693-5p. Identified proteins were cross-referenced with miRNA target prediction databases, followed by pathway enrichment analysis using Cytoscape. Significant proteins were validated by western blotting, and mitochondrial ROS was detected using Mitosox. Cellular proliferation and apoptosis were evaluated using the MTT assay and Hoechst staining. TNF-α regulates miR-4693-5p expression in RA-mimic SW982 cells. SWATH-MS identified 396 proteins, with 49 significantly regulated proteins. Among these, FN-1, YWHAZ, SOD2, and CALD1 were found to be directly regulated by miR-4693-5p. In vitro analysis showed that miR-4693-5p regulates ECM proteins, epithelial-to-mesenchymal transition (EMT), VEGF signaling, mitochondrial ROS, cell proliferation, and apoptosis. Identified protein expression was further validated in the CIA rat model. miR-4693-5p regulates pathways involving cell adhesion, cytoskeleton organization, angiogenesis, and cell death, highlighting its promise as a novel therapeutic target for improving RA treatment and disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.